Charles O'Bryan-Tear

Charles O'Bryan-Tear

Geen lopende functies

Vermogen: 215 961 $ op 31-03-2024

69 jaar
Health Technology
Consumer Services
Commercial Services

Profiel

Charles Gillies O'Bryan-Tear worked as a Medical Director at Bristol-Myers Squibb Pharmaceuticals Ltd., Director at Affibody AB, Interim Medical Director at Genzyme Therapeutics Ltd., Vice President-Research & Development at GlaxoSmithKline Biologicals NV, Chief Medical Officer at Algeta ASA, and Chief Medical Officer at Scancell Holdings Plc.
He holds a doctorate from the University of Cambridge and an MBA from Cranfield University.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
30-06-2023 120 373 ( 0.04% ) 215 961 $ 31-03-2024

Eerdere bekende functies van Charles O'Bryan-Tear

BedrijvenFunctieEinde
CLARITY PHARMACEUTICALS LTD Director/Board Member 15-05-2023
SCANCELL HOLDINGS PLC Chief Tech/Sci/R&D Officer -
Corporate Officer/Principal -
Corporate Officer/Principal -
ALGETA ASA Chief Tech/Sci/R&D Officer -
Ervaring van Charles O'Bryan-Tear in detail bekijken

Opleiding van Charles O'Bryan-Tear

University of Cambridge Doctorate Degree
Cranfield University Masters Business Admin

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Charles O'Bryan-Tear in detail bekijken

Verwante bedrijven

Beursgenoteerde bedrijven2
SCANCELL HOLDINGS PLC

Health Technology

CLARITY PHARMACEUTICALS LTD

Health Technology

Bedrijven in privébezit5

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

  1. Beurs
  2. Insiders
  3. Charles O'Bryan-Tear